Skip to main content

Table 1 Studies of cobalamin absorption, transport, cellular uptake and intracellular metabolism in a patient with a homozygous G425R mutation in ZFYVE20

From: Single point mutation in Rabenosyn-5 in a female with intractable seizures and evidence of defective endocytotic trafficking

Intrinsic Factor antibodies

Negative antibodies

Parietal Cell antibodies

Gastric Intrinsic Factor Protein (GIF)

No pathogenic mutations on WES (coverage × 30, last 5 exons of AMN × 3–5)

Cubilin (CUB)

Megalin (LRP2)

Amnioless (AMN)

Total Haptocorrin (TCN1)

592 pmol/L (normal 240-680)

Plasma Total Transcobalamin (TCNII)*

1520 pmol/L (normal 500-1.500)

Plasma Holotranscobalamin*

182 pmol/L (normal 40-160)

Transcobalamin Receptor related genes (TCbR, CD320, TCN1, TCN2)

Absence of (262_264delGAG and 297delA) by targeted mutation analysis [17]

No pathogenic mutations by WES (coverage > × 20)

[14C]-propionate incorporation (f)

11.0 nmol/mg protein/18 h (normal 10.8 ± 3.7 nmol/mg protein/18 h)

[14C]-methylene tetrahydrofolate incorporation (f)

250 pmol/mg protein/18 h (normal 225 ± 165 pmol/mg protein/18 h)

[57Co]-cyanocobalamin uptake (f)

16.9 pg/106 cells (normal 13.2 ± 4.8 pg/106)

[57Co]-cyanocobalamin conversion to adenosylcobalamin (f)

5.7. % of intracellular cobalamin (normal 15.3 ± 4.2)

[57Co]-cyanocobalamin coversion to methylcobalamin (f)

53.0% (normal 58.0 ± 6.7)